Lobular in situ neoplasia and columnar cell lesions: Diagnosis in breast core biopsies and implications for management

Pathology

Volumn 39, Issue 2, 2007, Pages 208-216

  Pinder, Sarah E ^a   Provenzano, Elena ^a   Reis Filho, Jorge S ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Atypical lobular hyperplasia; Columnar cell change; Columnar cell lesion; Flat epithelial atypia; Lobular carcinoma in situ; Lobular neoplasia

Indexed keywords

APOCRINE GLAND; BREAST BIOPSY; BREAST HYPERPLASIA; BREAST TUMOR; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER INFILTRATION; CANCER INVASION; CARCINOMA IN SITU; CELL ADHESION; CELL DIFFERENTIATION; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; PLEOMORPHIC ADENOMA; PROTEIN EXPRESSION; REVIEW; TISSUE SECTION;

EID: 33947325359     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020701230849     Document Type: Article

References (91)

1. Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary carcinoma. Am J Pathol 1941; 17: 491-9.
2. Ewing J. Neoplastic Diseases: A Textbook on Tumors. Philadelphia: WB Saunders, 1919.
3. Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978; 42: 737-69.
4. Page DL, Kidd TE Jr, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991; 22: 1232-9.
5. Simpson PT, Gale T, Fulford LG, et al. The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res 2003; 5: 258-62.
6. Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 2005; 23: 5534-41.
7. Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985; 55: 2698-708.
8. Non-operative Diagnosis Subgroup of the National Coordinating Group for Breast Screening Pathology. Guidelines for Non-operative Diagnostic Procedures and Reporting in Breast Cancer Screening. Sheffield: NHS Cancer Screening Programmes, 2001; NHS BSP Publication No50.
9. Page DL, Anderson TJ, Rogers LW. Carcinoma in situ (CIS). In: Page DL, Anderson TJ, editors. Diagnostic Histopathology of the Breast. New York: Churchill Livingstone, 1987; 157-92.
10. Haagensen CD. Diseases of the breast. Philadelphia: WB Saunders, 1971.
11. Sneige N, Wang J, Baker BA, et al. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol 2002; 15: 1044-50.
12. Wheeler JE, Enterline HT, Roseman JM, et al. Lobular carcinoma in situ of the breast. Long-term followup. Cancer 1974; 34: 554-63.
13. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol 1992; 23: 655-62.
14. Reis-Filho JS, Simpson PT, Jones C, et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 2005; 207: 1-13.
15. Chen Y, Fitzgibbons P, Jacobs T, et al. Pleomorphic apocrine lobular carcinoma in situ (PALCIS): Phenotypic and genetic study of a distinct-variant of lobular carcinoma in situ (LCIS). Lab Invest 2005; 85: 29A.
16. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol 1992; 23: 655-62.
17. Frolik D, Caduff R, Varga Z. Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas. Histopathology 2001; 39: 503-13.
18. Maluf HM. Differential diagnosis of solid carcinoma in situ. Semin Diagn Pathol 2004; 21: 25-31.
19. Maluf HM, Swanson PE, Koerner FC. Solid low-grade in situ carcinoma of the breast: role of associated lesions and E-cadherin in differential diagnosis. Am J Surg Pathol 2001; 25: 237-44.
20. Jacobs TW, Pliss N, Kouria G, et al. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol 2001; 25: 229-36.
21. De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997; 183: 404-11.
22. Vos CB, Cleton-Jansen AM, Berx G, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer 1997; 76: 1131-3.
23. Berx G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996; 13: 1919-25.
24. Mastracci TL, Tjan S, Bane AL, et al. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol 2005; 18: 741-51.
25. Sarrio D, Perez-Mies B, Hardisson D, et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 2004; 23: 3272-83.
26. Bratthauer GL, Moinfar F, Stamatakos MD, et al. Combined Ecadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. Hum Pathol 2002; 33: 620-7.
27. Bratthauer GL, Miettinen M, Tavassoli FA. Cytokeratin immunoreactivity in lobular intraepithelial neoplasia. J Histochem Cytochem 2003; 51: 1527-31.
28. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006; 25: 5846-53.
29. Fulford LG, Reis-Filho JS, Lakhani SR. Lobular in situ neoplasia. Curr Diagn Pathol 2004; 10: 183-92.
30. Fraser JL, Raza S, Chorny K, Connolly JL, Schnitt SJ. Columnar alteration with prominent apical snouts and secretions: a spectrum of changes frequently present in breast biopsies performed for microcalcifications. Am J Surg Pathol 1998; 22: 1521-7.
31. McLaren BK, Gobbi H, Schuyler PA, et al. Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: a nested case-control study. Am J Surg Pathol 2005; 29: 105-10.
32. Azzopardi JG. Problems in Breast Pathology. Philadelphia: WB Saunders, 1978; 193-202.
33. Oyama T, Maluf H, Koerner F. Atypical cystic lobules: an early stage in the formation of low-grade ductal carcinoma in situ. Virchows Arch 1999; 435: 413-21.
34. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005; 143: 446-57.
35. Tavassoli FA, Hoefler H, Rosai J, et al. Intraductal proliferative lesions. In: Tavassoli FA, Devilee P, editors. Pathology and Genetics: Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003; 63-73.
36. Schnitt SJ, Vincent-Salomon A. Columnar cell lesions of the breast. Adv Anat Pathol 2003; 10: 113-24.
37. Simpson PT, Gale T, Reis-Filho JS, et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol 2005; 29: 734-46.
38. Fraser JLRS, Chorny K, Connolly JL, Schnitt SJ. Immunophenotype of columnar alteration with prominent apical snouts and secretions (CAPSS). Lab Invest 2000; 80: 21A.
39. Shoker BS, Jarvis C, Clarke RB, et al. Abnormal regulation of the oestrogen receptor in benign breast lesions. J Clin Pathol 2000; 53: 778-83.
40. Tremblay G, Deschenes J, Alpert L, Quenneville LA. Overexpression of estrogen receptors in columnar cell change and in unfolding breast lobules. Breast J 2005; 11: 326-32.
41. Rosen PP. Columnar cell hyperplasia is associated with lobular carcinoma in situ and tubular carcinoma. Am J Surg Pathol 1999; 23: 1561.
42. Sahoo S, Recant WM. Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast. Breast J 2005; 11: 140-2.
43. Cleton-Jansen AM. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 2002; 4: 5-8.
44. van Wezel T, Lombaerts M, van Roon EH, et al. Expression analysis of candidate breast tumour suppressor genes on chromosome 16q. Breast Cancer Res 2005; 7: R998-1004.
45. Rakha EA, Green AR, Powe DG, et al. Chromosome 16 tumorsuppressor genes in breast cancer. Genes Chromosomes Cancer 2006; 45: 527-35.
46. Roylance R, Droufakou S, Gorman P, et al. The role of E-cadherin in low-grade ductal breast tumourigenesis. J Pathol 2003; 200: 53-8.
47. Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004; 41: 508-17.
48. Sarrio D, Moreno-Bueno G, Hardisson D, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2003; 106: 208-15.
49. Droufakou S, Deshmane V, Roylance R, et al. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001; 92: 404-8.
50. Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004; 41: 508-17.
51. Lu YJ, Osin P, Lakhani SR, et al. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res 1998; 58: 4721-7.
52. Buerger H, Simon R, Schafer KL, et al. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol Pathol 2000; 53: 118-21.
53. Etzell JE, Devries S, Chew K, et al. Loss of chromosome 16q in lobular carcinoma in situ. Hum Pathol 2001; 32: 292-6.
54. Shelley Hwang E, Nyante SJ, Yi Chen Y, et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 2004; 100: 2562-72.
55. Loo LW, Grove DI, Williams EM, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004; 64: 8541-9.
56. Reis-Filho JS, Simpson PT, Turner NC, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006; 12: 6652-62.
57. Morandi L, Marucci G, Foschini MP, et al. Genetic similarities and differences between lobular in situ neoplasia (LN) and invasive lobular carcinoma of the breast. Virchows Arch 2006; 449: 14-23.
58. Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ('clinging ductal carcinoma in situ'): a simulator of normal mammary epithelium. Cancer 2000; 88: 2072-81.
59. Simpson PT, Gale T, Reis-Filho JS, et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol 2005; 29: 734-46.
60. Dabbs DJ, Carter G, Fudge M, Peng Y, Swalsky P, Finkelstein S. Molecular alterations in columnar cell lesions of the breast. Mod Pathol 2006; 19: 344-9.
61. Page DL, Schuyler PA, Dupont WD, et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003; 361: 125-9.
62. Fisher ER, Land SR, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer 2004; 100: 238-44.
63. Maluf H, Koerner F. Lobular carcinoma in situ and infiltrating ductal carcinoma: frequent presence of DCIS as a precursor lesion. Int J Surg Pathol 2001; 9: 127-31.
64. Ho BC, Tan PH. Flat epithelial atypia: concepts and controversies of an intraductal lesion of the breast. Pathology 2005; 37: 105-111.
65. Eusebi V, Feudale E, Foschini MP, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994; 11: 223-35.
66. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinomain-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001; 19: 2263-71.
67. de Mascarel I, MacGrogan G, Picot V, Douggaz A, Mathoulin- Pélissier S. Results of a long term follow-up study of 115 patients with flat epithelial atypia. Lab Invest 2006; 86: 25A.
68. Schnitt SJ. The diagnosis and management of pre-invasive breast disease: flat epithelial atypia - classification, pathologic features and clinical significance. Breast Cancer Res 5: 263-268.
69. Middleton LP, Grant S, Stephens T, et al. Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised? Mod Pathol 2003; 16: 120-9.
70. Jacobs TW, Connolly JL, Schnitt SJ. Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Am J Surg Pathol 2002; 26: 1095-110.
71. Crisi GM, Mandavilli S, Cronin E, et al. Invasive mammary carcinoma after immediate and short-term follow-up for lobular neoplasia on core biopsy. Am J Surg Pathol 2003; 27: 325-33.
72. O'Driscoll D, Britton P, Bobrow L, et al. Lobular carcinoma in situ on core biopsy-what is the clinical significance? Clin Radiol 2001; 56: 216-20.
73. Shin SJ, Rosen PP. Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Arch Pathol Lab Med 2002; 126: 697-701.
74. Renshaw AA, Derhagopian RP, Martinez P, et al. Lobular neoplasia in breast core needle biopsy specimens is associated with a low risk of ductal carcinoma in situ or invasive carcinoma on subsequent excision. Am J Clin Pathol 2006; 126: 310-3.
75. Renshaw AA, Cartagena N, Schenkman RH, et al. Atypical ductal hyperplasia in breast core needle biopsies. Correlation of size of the lesion, complete removal of the lesion, and the incidence of carcinoma in follow-up biopsies. Am J Clin Pathol 2001; 116: 92-6.
76. Bauer VP, Ditkoff BA, Schnabel F, et al. The management of lobular neoplasia identified on percutaneous core breast biopsy. Breast J 2003; 9: 4-9.
77. Dmytrasz K, Tartter PI, Mizrachy H, et al. The significance of atypical lobular hyperplasia at percutaneous breast biopsy. Breast J 2003; 9: 10-2.
78. Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol 2005; 29: 534-43.
79. Mahoney MC, Robinson-Smith TM, Shaughnessy EA. Lobular neoplasia at 11-gauge vacuum-assisted stereotactic biopsy: correlation with surgical excisional biopsy and mammographic follow-up. AJR Am J Roentgenol 2006; 187: 949-54.
80. Liberman L, Sama M, Susnik B, et al. Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings. AJR Am J Roentgenol 1999; 173: 291-9.
81. Lee AH, Denley HE, Pinder SE, et al. Excision biopsy findings of patients with breast needle core biopsies reported as suspicious of malignancy (B4) or lesion of uncertain malignant potential (B3). Histopathology 2003; 42: 331-6.
82. Margenthaler JA, Duke D, Monsees BS, Barton PT, Clark C, Dietz JR. Correlation between core biopsy and excisional biopsy in breast highrisk lesions. Am J Surg 2006; 192: 534-7.
83. Arpino G, Allred DC, Mohsin SK, Weiss HL, Conrow D, Elledge RM. Lobular neoplasia on core-needle biopsy - clinical significance. Cancer 2004; 101: 242-50.
84. Lim CN, Ho BC, Bay BH, Yip G, Tan PH. Nuclear morphometry in columnar cell lesions of the breast: is it useful? J Clin Pathol 2006; Epub ahead of print.
85. Brogi E, Tan LK. Findings at excisional biopsy (EBX) performed after identification of columnar cell change (CCC) of ductal epithelium in breast core biopsy (CBX). Mod Pathol 2002; 5: 9A-30.
86. Harigopal MYD, Hoda SA, DeLellis RA, Vazquez MF. Columnar cell alteration diagnosed on mammotome core biopsy for indeterminate microcalcifications: Results of subsequent mammograms and surgical excision. Mod Pathol 2002; 15: 6.
87. Nasser S, Fan MJ. Does atypical columnar cell hyperplasia on breast core biopsy warrant follow-up excision? Mod Pathol 2003; 16: 2A.
88. Kunju LP, Kleer CG. Significance of flat epithelial atypia (FEA) on mammotome core needle biopsy: Should it be excised? Lab Invest 2006; 86: 32A.
89. Lubelsky SM, Bane AL, Shin V, Kulkarni S, O'Malley FP. Columnar cell lesions and flat epithelial atypia: Incidence and significance in a mammographically screened population. Lab Invest 2005; 85: 41A.
90. Bai H, Sung CJ, Wu Q, et al. Flat epithelial atypia in breast needle core biopsies: A correlative followup study. Lab Invest 2005; 85: 25A.
91. Xu C, Chung A, Giri D. Diagnosis of columnar cell change with atypia on breast core biopsy: Impact of inter-observer variability, degree of atypia and the volume of lesional changes on surgical management. Lab Invest 2005; 85: 55A.